Fresenius Medical Care : published form 20-F for the fiscal year 2020

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Annual Results Fresenius Medical Care AG & Co. KGaA published form 20-F for the fiscal year 2020 24.02.2021 / 10:51 The issuer is solely responsible for the content of this announcement. Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has filed the annual report 2020 on form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company's website (freseniusmedicalcare.com) in the "Investors" section as well as at the SEC's website (www.sec.gov). A hard copy of Fresenius Medical Care's annual report on form 20-F including the complete audited financial statements may be obtained from the company free of charge upon request to the company's Investor Relations department by email at [e-mail]. The company also published a Facts & Figures 2020 website at factsandfigures.fmc-ag.com to provide an overview of the key financial figures for the fiscal year 2020. In addition, the new Corporate Magazine, Company Profile as well as a Five-Year-Summary are available for download. Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.7 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,092 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 346,553 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the Company's website at www.freseniusmedicalcare.com and factsandfigures.fmc-ag.com. Disclaimers This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. Contact: Dr. Dominik Heger EVP I Head of Investor Relations, Strategic Development & Communications [e-mail] P. [phone] 24.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:	English
Company:	Fresenius Medical Care AG & Co. KGaA
	Else-Kröner-Straße 1
	61352 Bad Homburg
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.freseniusmedicalcare.com
ISIN:	DE0005785802
WKN:	578580
Indices:	DAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange
EQS News ID:	1170744

End of News	DGAP News Service

1170744  24.02.2021